American Lawyer Highlights “Blockbuster” VW Emissions Settlement in Year-End Roundup

Scales of Justice in courtroom

The American Lawyer takes a look back at how the plaintiffs’ bar fared for better and for worse in 2016, including a report on the “blockbuster” $14.7 billion settlement in the Volkswagen diesel emissions consumer fraud case that surpassed previous automotive industry records and may well have set an all-time speed and efficiency record for a case of its size, running from inception to resolution in less than a year. [Read more…]

Rachel Geman Looks Ahead to EEOC Under Trump In Q&A with Bloomberg BNA

Rachel Geman Looks Ahead to EEOC Under Trump In Q&A with Bloomberg BNA

Bloomberg BNA spoke with Lieff Cabraser partner Rachel Geman for a Q&A on upcoming cases involving the Equal Employment Opportunity Commission (EEOC) and anticipated employment law enforcement under President-elect Donald Trump’s incoming administration.

[Read more…]

Law360 Highlights the Top 5 Multidistrict Litigation Matters of 2016

Law360 Highlights the Top 5 Multidistrict Litigation Matters of 2016

Law360 reviews a list of “Top 5 Multidistrict Litigation Matters,” covering large-scale cases “sure to make headlines in 2017,” all of which include some involvement by Lieff Cabraser. These highly visible multi-district litigation matters include: General Motors Ignition-Switch defects, DePuy Pinnacle Hip injuries, Xarelto (Rivaroxaban) blood thinner injuries, Volkswagen “Clean Diesel” Emissions consumer fraud, and Pelvic Surgical Mesh injuries. [Read more…]

U.S. Vehicle Safety Officials Investigating Fiat Chrysler Roll-Away Crashes

U.S. Vehicle Safety Officials Investigating Fiat Chrysler Roll-Away Crashes

The National Highway Traffic Safety Administration (NHTSA) is investigating a potential Fiat Chrysler auto defect, in which the vehicles roll away despite being shifted into park. U.S. auto safety regulators will be inspecting about 1 million 2013-2016 model year Ram 1500 pickup trucks and 2014-2016 Dodge Durango SUVs in the wake of numerous vehicle roll-away reports. These auto injury reports have included nine injuries and 25 crashes so far. [Read more…]

New Stryker Rejuvenate and Stryker ABG II Hip Implant Injuries Settlement Announced

New Stryker Rejuvenate and Stryker ABG II Hip Implant Injuries Settlement Announced

Stryker Orthopaedics has announced that it has reached a settlement with plaintiffs in both federal multidistrict litigation and New Jersey multicounty litigation over injury claims relating to Rejuvenate and ABG II hip implants. The settlement will compensate eligible U.S. patients who had surgery to replace their hip stems (known as revision surgery) prior to December 19, 2016. [Read more…]

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

Lexi Hazam Named to Plaintiffs Executive Committee in Nationwide Abilify Drug Injury Litigation

On December 16, 2016, Chief Judge M. Casey Rodgers of the U.S. District Court for the Northern District of Florida issued an order appointing Lexi J. Hazam of Lieff Cabraser to the Plaintiffs’ Executive Committee in the multidistrict litigation previously consolidated in October 2016 over injuries and financial losses sustained by patients as a result of their use of the prescription drug Abilify. [Read more…]

Class Action Settlement Announced in Google Message Scanning Privacy Lawsuit

Class Action Settlement Announced in Google Message Scanning Privacy Lawsuit

A settlement has been reached in the class action digital privacy litigation against Google Inc. regarding claims that the popular Gmail service scanned some outgoing user email messages to build marketing profiles and serve targeted ads. [Read more…]

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Bristol-Myers Squibb Pays $19.5 Million Over Improper Abilify Drug Marketing

Bristol-Myers Squibb has agreed to pay $19.5 million to settle claims of improper advertising relating to its top-selling drug Abilify. 42 states and Washington D.C. alleged that the company improperly advertised antipsychotic drug Abilify, first approved in 2002 by the FDA to treat schizophrenic in adults. However, Bristol-Myers Squibb thereafter began promoting Abilify for off-label uses not approved by the FDA. These off-label uses had not been established as safe or effective. [Read more…]